Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Maen Hussein,1 Marina Maglakelidze,2 Donald A Richards,3 Marielle Sabatini,4 Todd A Gersten,5 Keith Lerro,6 Ivan Sinielnikov,7 Alexander Spira,8,9 Yili Pritchett,10 Joyce M Antal,10 Rajesh Malik,10 J Thaddeus Beck11 1Florida Cancer Specialists, Leesburg, FL, USA; 2LLC Arensia Exploratory Medicine, T...

Full description

Bibliographic Details
Main Authors: Hussein M, Maglakelidze M, Richards DA, Sabatini M, Gersten TA, Lerro K, Sinielnikov I, Spira A, Pritchett Y, Antal JM, Malik R, Beck JT
Format: Article
Language:English
Published: Dove Medical Press 2021-08-01
Series:Cancer Management and Research
Subjects:
trilaciclib
myelosuppression
myeloprotection
myelopreservation
chemotherapy
small cell lung cancer
Online Access:https://www.dovepress.com/myeloprotective-effects-of-trilaciclib-among-patients-with-small-cell--peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/myeloprotective-effects-of-trilaciclib-among-patients-with-small-cell--peer-reviewed-fulltext-article-CMAR

Similar Items